GlassScriptPhysician profile
Rachel Lynch
NPI 1801354071
$4,954.57
in general payments reported to CMS, 2019-2025
31 companies · $927 in 2025
The $927 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,058 · 2022: $1,229 · 2023: $881 · 2024: $860 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,667.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $908.68 | 2021-2025 | |
| Novo Nordisk INC | $801.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $457.72 | 2021-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $453.53 | 2022-2025 | |
| Lilly USA, LLC | $389.19 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $319.93 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $306.48 | 2022-2025 | Airsupra, Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $181.20 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $144.08 | 2021 | |
| Glaxosmithkline, LLC. | $129.69 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Optinose US, INC. | $100.75 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $87.67 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $82.02 | 2022-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.71 | 2025 | Caplyta |
| Eisai INC. | $52.46 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $51.80 | 2023-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $48.17 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $43.48 | 2021-2022 | |
| Corium, LLC | $42.62 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $41.09 | 2021-2023 | |
| Medtronic, INC. | $39.02 | 2025 | Inceptiv, Intellis Adaptivestim |
| Vivus LLC | $36.50 | 2021 | |
| Adlon Therapeutics L.P. | $24.35 | 2021 | |
| Shield Therapeutics INC | $23.70 | 2025 | |
| Hologic Sales and Service, LLC | $18.78 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.18 | 2022 | |
| Merck Sharp & Dohme LLC | $17.04 | 2022 | |
| Almatica Pharma LLC | $16.70 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.21 | 2025 | Gvoke Hypopen |
| Mylan Specialty L.P. | $14.32 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.